Practical Guidance on Optimizing CLL Care in the Era of Molecular Therapies

How do you treat patients with newly diagnosed CLL in the era of new agents? In this commentary, Dr. Flinn discusses emerging frontline combination regimens for the treatment of CLL.

Ian W. Flinn, MD, PhD Released: May 3, 2019

Are you aware of some of the latest clinical data in CLL? In this commentary, I will discuss 3 key studies on venetoclax, acalabrutinib, and lisocabtagene maraleucel in CLL that were presented at ASCO 2019.

Susan M. O'Brien, MD Released: June 27, 2019

Farrukh Awan, MD, MS, discusses recent advances and clinical data in CLL that led to an updated online treatment decision support tool for CLL from Clinical Care Options.

Farrukh T. Awan, MD Released: November 13, 2019

Acalabrutinib is now approved for treating patients with CLL. Are you ready to incorporate it into your practice?

Nicole Lamanna, MD Released: January 10, 2020

In this CME-certified interactive virtual presentation, gain case-based expert insights on incorporating targeted therapies into the treatment paradigm for CLL.

Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: February 14, 2020 Expired: No longer available for credit

Download these slides to review the most recent clinical data on targeted therapies in both frontline and relapsed/refractory CLL.

Jeff P. Sharman, MD Released: February 14, 2020

Jeff P. Sharman, MD; Nichole Fisher, RN, BSN; and Emily Bucholtz, RPh, review patient cases and supporting clinical data to provide guidance on optimizing care for chronic lymphocytic leukemia.

Emily Bucholtz, RPh Nichole Fisher, RN, BSN Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: July 17, 2019 Expired: No longer available for credit

Download these slides to review the most recent clinical data on new agents in both frontline and relapsed/refractory CLL.

Emily Bucholtz, RPh Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: July 17, 2019

Download this PDF resource to review the current treatment algorithm and key clinical trials in CLL.

Andrew D. Zelenetz, MD, PhD
Program Director Released: September 10, 2019